Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases

Adagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial activity in KRASG12C-mutated NSCLC with untreated CNS metastases 
Data demonstrate compelling... | June 20, 2023

Related Keywords

,Alan Sandler ,Twitter ,Mirati Therapeutics Inc ,Linkedin ,Prnewswire Mirati Therapeutics Inc ,Exchange Commission ,Facebook ,Nasdaq ,National Comprehensive Cancer Network ,Clinical Practice Guidelines ,Clinical Oncology ,Mirati Therapeutics ,Accelerated Approval ,Time Oncology Review ,Marketing Authorization Application ,Breakthrough Therapy Designation ,Prescribing Information ,Nc Stock Exchange ,News ,Information ,Press Release ,Adagrasib ,Us ,The ,First ,End ,Only ,Rasg12c ,Inhibitor ,O ,Prospectively ,Emonstrate ,Intracranial ,Activity ,N ,Nsclc ,Ith ,Untreated ,Ns ,Emonstrate Mrtx Us60468t1051 ,